215 related articles for article (PubMed ID: 28639536)
1. Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis.
Foley RW; Tagg NT; Schindler MK; Fenton KM; Reich DS; Cortese I; Mowry EM
Mult Scler; 2017 Sep; 23(10):1424-1427. PubMed ID: 28639536
[TBL] [Abstract][Full Text] [Related]
2. Considerations for using Natalizumab treatment in patients with a history of choroidal melanoma.
Kaye AE; Hawkes ED; Gout II; El-Amir AN; Neffendorf JE
Mult Scler Relat Disord; 2018 Nov; 26():74-76. PubMed ID: 30237107
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary paracoccidioidomycosis associated with the use of natalizumab in multiple sclerosis.
Almeida KJ; Barreto-Soares RV; Campos-Sousa RN; Campos-Sousa MG; Bor-Seng-Shu E
Mult Scler; 2018 Jun; 24(7):1002-1004. PubMed ID: 29649930
[TBL] [Abstract][Full Text] [Related]
4. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
Rath L; Vijiaratnam N; Skibina O
Intern Med J; 2017 Feb; 47(2):194-199. PubMed ID: 27862809
[TBL] [Abstract][Full Text] [Related]
5. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
Wipfler P; Oppermann K; Pilz G; Afazel S; Haschke-Becher E; Harrer A; Huemer M; Kunz A; Golaszewski S; Staffen W; Ladurner G; Kraus J
Mult Scler; 2011 Jan; 17(1):16-23. PubMed ID: 20937631
[TBL] [Abstract][Full Text] [Related]
6. Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.
Shirani A; Stüve O
J Immunol; 2017 Feb; 198(4):1381-1386. PubMed ID: 28167648
[TBL] [Abstract][Full Text] [Related]
7. Three cases of herpes zoster radiculitis in MS patients treated with natalizumab.
Yamout BI; Abou Zeid N; Taha AJ; Zeineddine MM; Khoury SJ
Mult Scler Relat Disord; 2016 Sep; 9():122-4. PubMed ID: 27645358
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
Lanza Cariccio V; Bramanti P; Mazzon E
Mult Scler Relat Disord; 2018 Feb; 20():93-99. PubMed ID: 29353737
[TBL] [Abstract][Full Text] [Related]
9. Emergence of rheumatoid arthritis following exposure to natalizumab.
Su E; Novic J; Han MH
Mult Scler Relat Disord; 2020 May; 40():101936. PubMed ID: 31982664
[TBL] [Abstract][Full Text] [Related]
10. Natalizumab treatment for multiple sclerosis inducing a toxic acute myocardial damage. Is there any relationship?
Fama' F; Dattola V; Cicciu' M; Buccafusca M; Russo M; Lo Presti D; Dattilo G; Di Bella G
Int J Cardiol; 2016 Mar; 206():127-8. PubMed ID: 26788687
[No Abstract] [Full Text] [Related]
11. Cerebral abscess in a multiple sclerosis patient during treatment with natalizumab.
Durmus B; Van Goethem J; Vercruyssen A; De la Meilleure G; Jadoul C; Willekens B
Acta Neurol Belg; 2020 Feb; 120(1):215-217. PubMed ID: 30953297
[No Abstract] [Full Text] [Related]
12. Reversible hyporegenerative anemia during natalizumab treatment.
Monteleone F; Buccisano F; Boffa L; Buttari F; Di Veroli A; Borriello G; Rossi S; Centonze D
Mult Scler; 2015 Feb; 21(2):257-8. PubMed ID: 25186208
[No Abstract] [Full Text] [Related]
13. Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis.
Dubey D; Cano CA; Stüve O
Curr Opin Neurol; 2016 Jun; 29(3):278-85. PubMed ID: 27027553
[TBL] [Abstract][Full Text] [Related]
14. Long-lasting severe anemia following treatment with natalizumab for relapsing-remitting multiple sclerosis: a case report.
Hamnvik LHD; Tjønnfjord GE; Spetalen S; Dalgaard J
J Med Case Rep; 2024 May; 18(1):245. PubMed ID: 38736000
[TBL] [Abstract][Full Text] [Related]
15. Severe thrombocytopenia during Natalizumab therapy: A case report.
Rini AM; Clerici VT; Rinaldi E; Modesto M; Pastore D; Confalonieri PA; Passarella B
J Neurol Sci; 2020 Feb; 409():116587. PubMed ID: 31805430
[No Abstract] [Full Text] [Related]
16. Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis.
Nakamura M; Itani K; Miyake K; Kunieda T; Kaneko S; Kusaka H
Intern Med; 2017; 56(2):211-214. PubMed ID: 28090055
[TBL] [Abstract][Full Text] [Related]
17. Neonatal pancytopenia in a child, born after maternal exposure to natalizumab throughout pregnancy.
Guilloton L; Pegat A; Defrance J; Quesnel L; Barral G; Drouet A
J Gynecol Obstet Hum Reprod; 2017 Mar; 46(3):301-302. PubMed ID: 28403930
[TBL] [Abstract][Full Text] [Related]
18. High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - YES.
Yap SM; McGuigan C
Mult Scler; 2017 May; 23(6):765-767. PubMed ID: 28287039
[No Abstract] [Full Text] [Related]
19. Arthritic psoriasis during natalizumab treatment: a case report and review of the literature.
Vacchiano V; Foschi M; Sabattini L; Scandellari C; Lugaresi A
Neurol Sci; 2018 Jan; 39(1):181-183. PubMed ID: 28905124
[No Abstract] [Full Text] [Related]
20. Immune reconstitution inflammatory syndrome and natalizumab-Is it possible before removing the drug?
Mulero P; Neri MJ; Rodriguez M; Arenillas JF; Téllez N
Mult Scler Relat Disord; 2014 Sep; 3(5):659-61. PubMed ID: 26265277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
